What to Expect From Charles River Laboratories' Q3 2025 Earnings Report

Core Insights - Charles River Laboratories International, Inc. (CRL) is valued at a market cap of $9.2 billion and provides drug discovery, non-clinical development, and safety testing services, partnering with various institutions to accelerate research and drug development [1] Financial Performance - Analysts expect CRL to report a profit of $2.32 per share for fiscal Q3 2025, a decrease of 10.4% from $2.59 per share in the same quarter last year [2] - For fiscal 2025, CRL is projected to report a profit of $10.17 per share, down 1.5% from $10.32 per share in fiscal 2024, but is expected to rebound to $10.71 per share in fiscal 2026, reflecting a year-over-year growth of 5.3% [3] Stock Performance - Over the past 52 weeks, CRL has gained marginally, underperforming the S&P 500 Index's 14.5% increase but outperforming the Health Care Select Sector SPDR Fund's 3.4% decline [4] Recent Earnings and Guidance - Following its Q2 earnings release, CRL's shares fell 10.3% despite better-than-expected results, with revenue of $1 billion and adjusted EPS of $3.12 exceeding consensus estimates [5] - The modest revenue growth was attributed to favorable foreign currency movements, while organic revenue declined due to weakness in the Discovery and Safety Assessment (DSA) segment [5] - In light of its Q2 results and expectations for a gradual recovery in the DSA segment, CRL raised its fiscal 2025 guidance, projecting adjusted EPS between $9.90 and $10.30, with revenue expected to decline modestly by 0.5% to 2.5% [6]